top of page
unlocking efficiency in pharma r&d
drug discovery is slow, risky, and expensive. daltontx is changing this by building adaptive ai systems that integrate into scientific workflows, learn with every experiment, and support scientists in real time, creating an intelligence backbone for modern r&d.
a new category for ai in pharma
instead of chasing their own pipeline, daltontx enables pharma and biotech at scale. the platform turns data into actionable insight, combines human expertise with agentic reasoning, and helps teams design and deliver breakthrough medicines faster. co-founders garry pairaudeau, adrian rossall, anthony bradley, and professor charlotte deane mbe bring decades of experience from astrazeneca, exscientia, and the university of oxford. together, they are rethinking how ai can accelerate the path from idea to impact.
related stories
bottom of page